-
1
-
-
34548491626
-
Prognostic factors for stage iii epithelial ovarian cancer: A gynecologic oncology group study
-
Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 3621-3627
-
-
Winter, W.E.1
Maxwell, G.L.2
Tian, C.3
-
2
-
-
0034213974
-
Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
-
Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
-
(2000)
Cancer.
, vol.88
, pp. 2584-2589
-
-
Sugiyama, T.1
Kamura, T.2
Kigawa, J.3
-
3
-
-
77949396071
-
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy
-
Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116: 1462-1468.
-
(2010)
Cancer.
, vol.116
, pp. 1462-1468
-
-
Bamias, A.1
Psaltopoulou, T.2
Sotiropoulou, M.3
-
4
-
-
34247156633
-
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
-
Crotzer DR, Sun CC, Coleman RL et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105:404-408.
-
(2007)
Gynecol Oncol.
, vol.105
, pp. 404-408
-
-
Crotzer, D.R.1
Sun, C.C.2
Coleman, R.L.3
-
5
-
-
77249088752
-
Trabectedin: A review of its use in soft tissue sarcoma and ovarian cancer
-
Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010;70:355-376.
-
(2010)
Drugs.
, vol.70
, pp. 355-376
-
-
Carter, N.J.1
Keam, S.J.2
-
6
-
-
33748035692
-
Cross-talk between nucleotide excision and homologous recombination dna repair pathways in the mechanism of action of antitumor trabectedin
-
Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66:8155-8162.
-
(2006)
Cancer Res.
, vol.66
, pp. 8155-8162
-
-
Herrero, A.B.1
Martín-Castellanos, C.2
Marco, E.3
-
7
-
-
0031848159
-
Ecteinascidin-743 a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
-
Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:1977-1983.
-
(1998)
Clin Cancer Res.
, vol.4
, pp. 1977-1983
-
-
Valoti, G.1
Nicoletti, M.I.2
Pellegrino, A.3
-
8
-
-
0032693607
-
High antitumour activity of et743 against human tumour xenografts from melanoma, nonysmall-cell lung and ovarian cancer
-
Hendriks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, nonYsmall-cell lung and ovarian cancer. Ann Oncol. 1999;10:1233-1240.
-
(1999)
Ann Oncol.
, vol.10
, pp. 1233-1240
-
-
Hendriks, H.R.1
Fiebig, H.H.2
Giavazzi, R.3
-
9
-
-
0037341360
-
Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis
-
Morioka H, Weissbach L, Vogel T, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res. 2003;9: 1211-1217.
-
(2003)
Clin Cancer Res.
, vol.9
, pp. 1211-1217
-
-
Morioka, H.1
Weissbach, L.2
Vogel, T.3
-
10
-
-
0141731283
-
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
-
Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 2003;63:5902-5908.
-
(2003)
Cancer Res.
, vol.63
, pp. 5902-5908
-
-
Donald, S.1
Verschoyle, R.D.2
Greaves, P.3
-
11
-
-
0035281734
-
Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patientsvpreliminary evidence of activity
-
Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patientsVpreliminary evidence of activity. J Clin Oncol. 2001;19:1248-1255.
-
(2001)
J Clin Oncol.
, vol.19
, pp. 1248-1255
-
-
Delaloge, S.1
Yovine, A.2
Taamma, A.3
-
12
-
-
1542398698
-
Phase ii study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
-
Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890-899.
-
(2004)
J Clin Oncol.
, vol.22
, pp. 890-899
-
-
Yovine, A.1
Riofrio, M.2
Blay, J.Y.3
-
13
-
-
72949084796
-
Trabectedin: An anticancer drug from the sea
-
Ganjoo KN, Patel SR. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother. 2009;10: 2735-2743.
-
(2009)
Expert Opin Pharmacother.
, vol.10
, pp. 2735-2743
-
-
Ganjoo, K.N.1
Patel, S.R.2
-
14
-
-
37049038819
-
A phase ii study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
-
Krasner CN, McMeekin DS, Chan S, et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007;97:1618-1624.
-
(2007)
Br J Cancer.
, vol.97
, pp. 1618-1624
-
-
Krasner, C.N.1
McMeekin, D.S.2
Chan, S.3
-
15
-
-
20144377216
-
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
-
Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23:1867-1874.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 1867-1874
-
-
Sessa, C.1
De Braud, F.2
Perotti, A.3
-
16
-
-
77955491837
-
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
-
Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-3114.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 3107-3114
-
-
Monk, B.J.1
Herzog, T.J.2
Kaye, S.B.3
-
17
-
-
84866736948
-
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
-
Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48:2361-2368.
-
(2012)
Eur J Cancer.
, vol.48
, pp. 2361-2368
-
-
Monk, B.J.1
Herzog, T.J.2
Kaye, S.B.3
-
18
-
-
79960329488
-
The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary
-
Mabuchi S, Hisamatsu T, Kawase C, et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res. 2011;17:4462-4473.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 4462-4473
-
-
Mabuchi, S.1
Hisamatsu, T.2
Kawase, C.3
-
19
-
-
69949109923
-
Mtor is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
-
Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009;15:5404-5413.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 5404-5413
-
-
Mabuchi, S.1
Kawase, C.2
Altomare, D.A.3
-
20
-
-
0034047312
-
Phase i dose-finding and pharmacokinetic trial of irinotecan hydrochloride (cpt-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
-
Pitot HC, Goldberg RM, Reid JM, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res. 2000;6:2236-2244.
-
(2000)
Clin Cancer Res.
, vol.6
, pp. 2236-2244
-
-
Pitot, H.C.1
Goldberg, R.M.2
Reid, J.M.3
-
21
-
-
59449088659
-
Evaluation of lapatinib and topotecan combination therapy: Tissue culture, murine xenograft, and phase i clinical trial data
-
Molina JR, Kaufmann SH, Reid JM, et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res. 2008;14:7900-7908.
-
(2008)
Clin Cancer Res.
, vol.14
, pp. 7900-7908
-
-
Molina, J.R.1
Kaufmann, S.H.2
Reid, J.M.3
-
22
-
-
53049092830
-
A phase i study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
-
von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19:1802-1809.
-
(2008)
Ann Oncol.
, vol.19
, pp. 1802-1809
-
-
Von Mehren, M.1
Schilder, R.J.2
Cheng, J.D.3
-
23
-
-
0142089888
-
The combination of yondelis and cisplatin is synergistic against human tumor xenografts
-
D'Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer. 2003;39:1920-1926.
-
(2003)
Eur J Cancer.
, vol.39
, pp. 1920-1926
-
-
D'Incalci, M.1
Colombo, T.2
Ubezio, P.3
-
24
-
-
0042878545
-
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
-
Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol. 2003;52:131-138.
-
(2003)
Cancer Chemother Pharmacol.
, vol.52
, pp. 131-138
-
-
Meco, D.1
Colombo, T.2
Ubezio, P.3
-
25
-
-
0034786774
-
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (et-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells
-
Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001;7:3251-3257.
-
(2001)
Clin Cancer Res.
, vol.7
, pp. 3251-3257
-
-
Takahashi, N.1
Li, W.W.2
Banerjee, D.3
-
26
-
-
24044480041
-
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft
-
Riccardi A, Meco D, Ubezio P, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs. 2005;16:811-815.
-
(2005)
Anticancer Drugs.
, vol.16
, pp. 811-815
-
-
Riccardi, A.1
Meco, D.2
Ubezio, P.3
-
27
-
-
0036279836
-
Pharmacology of topoisomerase i inhibitors irinotecan (cpt-11) and topotecan
-
Mathijssen RH, Loos WJ, Verweij J, et al. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets. 2002;2:103-123.
-
(2002)
Curr Cancer Drug Targets.
, vol.2
, pp. 103-123
-
-
Mathijssen, R.H.1
Loos, W.J.2
Verweij, J.3
-
28
-
-
18544367200
-
Inhibition of phosphorylation of bad and raf-1 by akt sensitizes human ovarian cancer cells to paclitaxel
-
Mabuchi S, Ohmichi M, Kimura A, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277:33490-33500.
-
(2002)
J Biol Chem.
, vol.277
, pp. 33490-33500
-
-
Mabuchi, S.1
Ohmichi, M.2
Kimura, A.3
-
29
-
-
33748994272
-
Role for drug transporters beyond tumor resistance: Hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity
-
Kroetz DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006;24:4225-4227.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 4225-4227
-
-
Kroetz, D.L.1
-
30
-
-
0032739648
-
Reversal of mdr1-Associated resistance to topotecan by pak-200s, a new dihydropyridine analogue, in human cancer cell lines
-
Vanhoefer U, Müller MR, Hilger RA, et al. Reversal of MDR1-Associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer. 1999;81:1304-1310.
-
(1999)
Br J Cancer.
, vol.81
, pp. 1304-1310
-
-
Vanhoefer, U.1
Müller, M.R.2
Hilger, R.A.3
|